Therefore, we conducted functional study using thyroid cancer cells with RAS mutation (KRAS mutation in Cal62 and HRAS mutation in HTH83) because high MFN2 expressed PTC are related with RAS-like gene expression. The gene discussed is KRAS; the disease is thyroid cancer.